Patents by Inventor Sreenivasu Mudumba
Sreenivasu Mudumba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8663639Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: GrantFiled: August 18, 2008Date of Patent: March 4, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Philippe J. M. Dor, Sreenivasu Mudumba, Thierry Nivaggioli, David A. Weber, Sidiq Farooq, Sudeep Takhar
-
Patent number: 8658667Abstract: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.Type: GrantFiled: June 24, 2013Date of Patent: February 25, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Thierry Nivaggioli, Sudeep Kaur Takhar
-
Patent number: 8637070Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: GrantFiled: February 9, 2006Date of Patent: January 28, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Publication number: 20140011834Abstract: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.Type: ApplicationFiled: June 24, 2013Publication date: January 9, 2014Inventors: Sreenivasu Mudumba, Thierry NIVAGGIOLI, Sudeep Kaur TAKHAR
-
Patent number: 8492400Abstract: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.Type: GrantFiled: February 9, 2007Date of Patent: July 23, 2013Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Thierry Nivaggioli, Sudeep Kaur Takhar
-
Patent number: 8367097Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: GrantFiled: May 12, 2010Date of Patent: February 5, 2013Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Publication number: 20120034279Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: October 21, 2011Publication date: February 9, 2012Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Eugene R. COOPER, David M. Kleinman, Thierry Nivaggioli, Philippe JM Dor, Sreenivasu Mudumba
-
Patent number: 7976867Abstract: A dermal, transdermal, mucosal or transmucosal delivery device is provided. The device includes a backing layer, defining an ingredient containing reservoir, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the dermis or mucosa.Type: GrantFiled: December 12, 2003Date of Patent: July 12, 2011Assignees: Schering-Plough Healthcare Products Inc., Corium InternationalInventors: Charles E. Lundy, Gary Wynn Cleary, Adrian Louis Faasse, Michael George Marcoux, Sreenivasu Mudumba
-
Publication number: 20100227879Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: ApplicationFiled: May 12, 2010Publication date: September 9, 2010Applicant: MacuSight, Inc.Inventors: Sreenivasu Mudumba, Philippe J.M. Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Publication number: 20090324690Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 14, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324689Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 13, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. COOPER, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324686Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: July 29, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J.M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324687Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: July 31, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Publication number: 20090324688Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: ApplicationFiled: August 12, 2009Publication date: December 31, 2009Applicant: MacuSight, Inc.Inventors: Eugene R. COOPER, David Kleinman, Thierry Nivaggioli, Philippe J. M. Dor, Sreenivasu Mudumba
-
Patent number: 7585517Abstract: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.Type: GrantFiled: September 20, 2004Date of Patent: September 8, 2009Assignee: Macusight, Inc.Inventors: Eugene R. Cooper, David M. Kleinman, Thierry Nivaggioli, Philippe J M Dor, Sreenivasu Mudumba
-
Publication number: 20090074786Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: ApplicationFiled: August 18, 2008Publication date: March 19, 2009Applicant: MacuSight, Inc.Inventors: Philippe J.M. Dor, Sreenivasu Mudumba, Thierry Nivaggioli, David A. Weber, Sidiq Farooq, Sudeep K. Takhar
-
Publication number: 20070203173Abstract: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.Type: ApplicationFiled: February 9, 2007Publication date: August 30, 2007Inventors: Sreenivasu Mudumba, Thierry Nivaggioli, Sudeep Takhar
-
Publication number: 20060264453Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: ApplicationFiled: February 9, 2006Publication date: November 23, 2006Applicant: MacuSight, Inc.Inventors: Sreenivasu Mudumba, Philippe Dor, Thierry Nivaggioli, David Weber, Sidiq Farooq
-
Publication number: 20060258698Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: ApplicationFiled: February 9, 2006Publication date: November 16, 2006Inventors: Sreenivasu Mudumba, Philippe Dor, Thierry Nivaggioli, David Weber, Sidiq Farooq
-
Publication number: 20060257450Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.Type: ApplicationFiled: March 21, 2006Publication date: November 16, 2006Inventors: Sreenivasu Mudumba, Philippe Jm Dor, Thierry Nivaggioli, David Weber, Sidiq Farooq